Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00256750 · ClinicalTrials.gov registry record · Phase 3
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 738
- Enrollment target
NCT00256750 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 738 participants.
The verdict
NCT00256750, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 738 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if Belatacept can provide protection from organ rejection following kidney transplantation while avoiding some of the toxic effects of standard immunosuppressive medications such as kidney damage. Effects on kidney function and patient survival as well as drug safety will also be studied.
Interventions
- DRUG Cyclosporine (CsA)
- DRUG Belatacept LI (less intensive)
- DRUG Belatacept MI (more intensive)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 738 participants |
| Start Date | 2005-03 |
| Est. Completion | 2015-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00256750
The ClinicalTrials.gov registry entry for NCT00256750 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 738 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclosporine (CsA) is the first listed.
NCT00256750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00256750 about?
NCT00256750 is a clinical study titled "Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)". The purpose of this study is to learn if Belatacept can provide protection from organ rejection following kidney transplantation while avoiding some of the toxic effects of standard immunosuppressive medications such as kidney damage. Effects on kidney function and patient survival as well as drug s...
What is the current status of trial NCT00256750?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 738 participants. The study started on 2005-03. Estimated completion is 2015-04.
What interventions are being tested in trial NCT00256750?
The interventions under investigation include: Cyclosporine (CsA) (DRUG), Belatacept LI (less intensive) (DRUG), Belatacept MI (more intensive) (DRUG).
Who is sponsoring clinical trial NCT00256750?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.